-
Rodman & Renshaw Initiates 'Unsung' Presbia With Buy; Stock Jumps
Tuesday, May 10, 2016 - 2:26pm | 452Read More...Rodman & Renshaw has started Presbia PLC (NASDAQ: LENS) with a Buy rating and $14 price target, saying the company is "an unsung company with an intriguingly positioned device in the attractive ophthalmics domain." Presbia makes the Flexivue Microlens for presbyopia (nearsightedness). The...
-
Rodman & Renshaw Believe LabStyle Innovations Is Driving Digital Diabetes Solutions
Monday, May 9, 2016 - 9:05am | 420Read More...Rodman & Renshaw analyst Raghuram Selvaraju believes LabStyle Innovations Corp (NASDAQ: DRIO) could more than double in a year from the current levels. The brokerage initiated coverage with a rating of Buy and a price target of $12.00 on valuation. The optimism was due to the development of an...
-
Synergy Pharma Seen 'Weighing' Options, Sell-Side Forecasts Upside Regardless Of M&A Rumors
Thursday, May 5, 2016 - 12:29pm | 489Read More...Like many small-cap biotech stocks, Synergy Pharmaceuticals Inc (NASDAQ: SGYP) is no stranger to the rumor mill. StreetInsider reported the company was exploring a sale on April 8, sending shares 8 percent higher. Bloomberg reported a similar rumor in March 2015, also yielding no follow-through...
-
StreetSweeper Short Bio-Path: 'Unfortunate' Analyst Support, Little Executive Biotech Experience
Tuesday, April 26, 2016 - 2:16pm | 593Read More...The Street Sweeper's Sonya Colberg published a scathing short thesis on Bio-Path Holdings Inc (NASDAQ: BPTH), a clinical-stage biotechnology company that focuses on developing drugs to fight cancer. Colberg's main criticism of the company is the fact that it "spent six years...
-
Amid Papa's Appointment, Rodman & Renshaw Still Buying Valeant
Tuesday, April 26, 2016 - 8:22am | 297Read More...On April 25, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that the former CEO of Perrigo Company plc Ordinary Shares (NYSE: PRGO), Joseph Papa, would replace the outgoing Mike Pearson as chairman and CEO. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on Valeant...
-
Rodman & Renshaw Doesn't Mind Valeant Default Notice, Says 'Unlikely' To Cause Concern Near-Term
Wednesday, April 13, 2016 - 11:07am | 317Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced on April 12 that it had received a notice of default from Centerbridge Partners L.P., one of its bond holders. Stating that this notice was not a cause for near term concern, Rodman & Renshaw’s Raghuram Selvaraju maintained a Buy...
-
Rodman & Renshaw Is Buying MagneGas, Likes Its Foray Into Alternative Green Gas
Wednesday, April 13, 2016 - 7:58am | 314Read More...MagneGas Corporation (NASDAQ: MNGA) manufactures an innovative metal-cutting gas, which has applications in the metal working, co-combustion and waste sterilization markets. Rodman & Renshaw’s Amit Dayal initiated coverage of the company with a Buy rating and a price target of $3. The...
-
Rodman & Renshaw Lowers Valeant's Target After Interest Expense Calculation, Still Sees $100+
Monday, April 11, 2016 - 10:54am | 256Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced last week it had reached an agreement with a majority of its creditors regarding a proposed amendment and waiver to its credit facility. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the company, while lowering...
-
Rodman & Renshaw Pounds Table On Valeant, Still Sees $118 Price After Credit Changes
Thursday, March 31, 2016 - 10:15am | 326Read More...On March 30, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) announced that it had started a process for an amendment and waiver to its existing credit facility. Rodman & Renshaw’s Raghuram Selvaraju reiterated a Buy rating on the company, with a price target of $118. Waiver And...
-
Rodman & Renshaw: Valeant Still Worth $118 Despite 'Soap Opera'
Tuesday, March 22, 2016 - 11:52am | 487Read More...Raghuram Selvaraju of Rodman & Renshaw reiterated his bullish stance on Valeant Pharmaceuticals Intl Inc (NYSE: VRX), a day after the company said its longtime CEO, Mike Pearson, would be stepping down and that he would continue to stay at the helm until his successor is identified....
-
Rodman & Renshaw Is Still Buying Valeant; Default Risk Still Manageable?
Monday, March 21, 2016 - 9:15am | 262Read More...Rodman & Renshaw’s Raghuram Selvaraj maintained a Buy rating for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), with a price target of $118. Debt default is the most substantial risk that the company is facing. Analyst Raghuram Selvaraj pointed out, “It is important to note that...
-
Several More Analysts Came Out On Valeant Today
Wednesday, March 16, 2016 - 4:36pm | 413Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) continued its downturn on Wednesday after the company released fourth quarter results with 2016 guidance revision that was far below expectations. Several more analysts put out their comments. Nomura's Shibani Malhotra downgraded Valeant to...
-
H.C. Wainwright: Valeant Story Still Intact
Wednesday, March 16, 2016 - 11:56am | 271Read More...HC Wainwright unit Rodman & Renshaw’s Raghuram Selvaraju, maintained a Buy rating for Valeant Pharmaceuticals Intl Inc (NYSE: VRX), while reducing the price target from $150 to $118, after the company lowered its guidance for 2016. Management reduced its 2016 revenue guidance from $12...
-
Digital Ally Falls 5% After Big Earnings Miss
Monday, March 7, 2016 - 4:30pm | 152Read More...Early Monday afternoon, Digital Ally, Inc. (NASDAQ: DGLY) reported quarterly results. The release may have been come sooner than planned.Falls Q4's EPS came in at $(0.40) versus an estimated $(0.18). Sales came in at $5.051 million versus the estimated $5.70 million. Following this...
-
Valeant Pharma: The Empire Strikes Back
Tuesday, February 16, 2016 - 10:18am | 370Read More...Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) have appreciated 17.21 percent over the past three months, while declining 0.35 percent over the past month. Rodman & Renshaw’s Raghuram Selvaraju has initiated coverage of the company with a Buy rating and price target of $150...
